Acute myeloid leukemia (AML) is a heterogeneous group of neoplastic disorders with great
variability in clinical course and response to therapy, as well as in the genetic and molecular …

Enhanced signaling through RAS and the mitogen‐associated protein kinase (MAPK)
cascade underlies the RASopathies, a family of clinically related disorders affecting …

Germline mutations in PTPN11, the gene encoding the protein tyrosine phosphatase SHP-2,
cause Noonan syndrome (NS) and the clinically related LEOPARD syndrome (LS), whereas …

Elucidation of the molecular mechanisms underlying carcinogenesis has benefited
tremendously from the identification and characterization of oncogenes and tumor …

▪ Abstract Noonan syndrome is a pleiomorphic autosomal dominant disorder with short
stature, facial dysmorphia, webbed neck, and heart defects. In the past decade, progress …

Reversible protein tyrosyl phosphorylation of cell surface receptors and downstream
intracellular transducers is a major regulatory mechanism used to modulate cellular …

Src homology 2 (SH2)-containing protein tyrosine phosphatase 2 (SHP2), encoded by the
human PTPN11 gene, is a ubiquitously expressed protein tyrosine phosphatase (PTP) that …

Shp2 tyrosine phosphatase plays a critical role in hematopoiesis, and dominant active
mutations have been detected in the human gene PTPN11, encoding Shp2, in child …

Acute myeloid leukaemia (AML) has been proposed to arise from the collaboration between
two classes of mutation, a class I, or proliferative, mutation and a class II, or blocking …

PTPN11, the gene which encodes protein tyrosine phosphatase SHP-2, plays an important
role in regulating intracellular signaling. Germline mutations in PTPN11 were first observed …